PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Trial Profile

PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2018

At a glance

  • Drugs Rose bengal sodium (Primary) ; Dacarbazine; Talimogene laherparepvec; Temozolomide
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Provectus Biopharmaceuticals
  • Most Recent Events

    • 27 Dec 2017 According to a Provectus Biopharmaceuticals media release, the study is enrolling in Germany, Italy and the U.S., and clinical trial authorizations have been received for France and Mexico.
    • 11 Jan 2017 Planned End Date changed from 1 Apr 2018 to 1 Oct 2018.
    • 11 Jan 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top